Music-based interventions for people with kidney failure undergoing haemodialysis.

Cochrane Database Syst RevOct 26, 2026 (epub)
Clinical ResearchNephrology

Hiroki Nishiwaki, William Mm Levack, Takeshi Hasegawa et al.

✦ AI-curated · Sources linked

In 30 seconds

This Cochrane systematic review and meta-analysis assessed randomised trials of music-based interventions in people with kidney failure receiving haemodialysis. It included 27 studies with 1,584 participants; 24 studies (1,467 participants) contributed to quantitative synthesis. The review found that music may reduce short-term fatigue: on the 10-point Piper Fatigue Scale, the mean difference was -3.14 (95% CI -3.83 to -2.45; 1 study, 62 participants), with low-certainty evidence. For several other outcomes, including blood pressure, the evidence was very uncertain.

Key findings

  • Music-based interventions may reduce short-term fatigue versus comparators (MD -3.14, 95% CI -3.83 to -2.45; 1 study, 62 participants; low-certainty evidence).
  • The effect on medium-term fatigue was very uncertain (SMD -1.99, 95% CI -3.92 to -0.06; I² = 91%; 2 studies, 86 participants).
  • Evidence for short-term blood pressure effects was very uncertain (MD -5.95, 95% CI -10.56 to -1.34; I² = 70%; 8 studies, 674 participants).

Why it matters

Symptoms such as fatigue, anxiety, depression and pain can substantially affect people receiving haemodialysis. This review evaluates music-based approaches as non-pharmacological interventions, but the limited and often uncertain evidence means their potential benefits should be interpreted cautiously. The findings also identify outcomes and follow-up periods where further reliable trials are needed.

What to keep in mind

Evidence certainty was low or very low for reported critical outcomes, and some estimates came from few participants or showed substantial heterogeneity. No studies assessed long-term fatigue or blood pressure.

Source

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.